ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,149.78
0.16%
Dow Jones
42,992.21
-0.77%
Gold vs US Dollar
2,624.17
0.00%
Brent Oil
73.815
0.26%
Bitcoin
93,463.73
-0.06%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Coeptis Therapeutics Holdings Inc (COEP)

  7. Coeptis Therapeutics Holdings Inc (COEP) News

Coeptis Therapeutics (COEP)

Coeptis Therapeutics Holdings Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:COEP
DateTimeSourceHeadlineSymbolCompany
27/12/202413:15PR Newswire (US)Coeptis Therapeutics Announces Reverse Stock SplitNASDAQ:COEPCoeptis Therapeutics Holdings Inc
26/12/202413:15PR Newswire (US)Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis TechnologiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
12/12/202413:00PR Newswire (US)Coeptis Therapeutics Unveils New Technology Division: Coeptis TechnologiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
03/12/202413:15PR Newswire (US)Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other IndustriesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
07/11/202413:07PR Newswire (US)Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical DevelopmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
24/10/202412:07PR Newswire (US)Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency UseNASDAQ:COEPCoeptis Therapeutics Holdings Inc
15/10/202412:07PR Newswire (US)Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell TherapyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
19/09/202411:07PR Newswire (US)Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
05/09/202412:07PR Newswire (US)Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to ShareholdersNASDAQ:COEPCoeptis Therapeutics Holdings Inc
16/08/202420:02Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
16/08/202420:01Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
14/08/202421:26Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:COEPCoeptis Therapeutics Holdings Inc
14/08/202421:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
31/07/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
20/06/202412:47PR Newswire (US)Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
30/05/202412:47PR Newswire (US)Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
08/05/202412:47PR Newswire (US)Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/05/202412:47PR Newswire (US)Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
02/04/202412:47PR Newswire (US)Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardNASDAQ:COEPCoeptis Therapeutics Holdings Inc
26/02/202414:00PR Newswire (US)Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKNASDAQ:COEPCoeptis Therapeutics Holdings Inc
07/02/202412:30PR Newswire (US)Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
04/01/202412:30PR Newswire (US)Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
31/10/202313:01PR Newswire (US)Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023NASDAQ:COEPCoeptis Therapeutics Holdings Inc
24/10/202312:30PR Newswire (US)Coeptis Therapeutics Announces $2 Million Private PlacementNASDAQ:COEPCoeptis Therapeutics Holdings Inc
11/10/202311:30PR Newswire (US)Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
09/10/202313:15PR Newswire (US)Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
04/10/202311:30PR Newswire (US)Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
27/09/202311:30PR Newswire (US)Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaNASDAQ:COEPCoeptis Therapeutics Holdings Inc
14/09/202311:30PR Newswire (US)Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionNASDAQ:COEPCoeptis Therapeutics Holdings Inc
11/09/202311:30PR Newswire (US)Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:COEP

Your Recent History

LSE
SRSP
Sirius Petroleum
LSE
AGL
Angle
LSE
ITM
Itm Power
LSE
BOO
Boohoo
LSE
PRIM
Primorus Investments
LSE
ALBA
Alba Mineral Resources
LSE
VAST
Vast Resources
LSE
QBT
Quantum Blockchain Techn...
LSE
WCAT
Wildcat Petroleum
LSE
SRES
Sunrise Resources
LSE
SUP
Supreme
LSE
MAST
Mast Energy Developments
LSE
ALTN
Altyngold
LSE
THG
Thg
LSE
HOC
Hochschild Mining
LSE
AAZ
Anglo Asian Mining
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads